Comparative Effectiveness Needs Holistic Value Measures – Amgen Exec

As momentum for payers to put more emphasis on pharmaceuticals' comparative effectiveness data, those involved in implementing CE programs need to recognize the "multi-dimensional" aspect of a drug's value, Amgen VP of Global Coverage & Reimbursement and Global Health Economics Josh Ofman said